retatrutide compounding Buy Peptide Dubai Retatrutide vs tirzepatide for weight

In December 2025, Eli Lilly announced topline results from the phase-3 TRIUMPH-4 clinical trial evaluating the safety and efficacy of retatrutide in adults with obesity or overweight and knee osteoarthritis, and without diabetes, as an adjunct to healthy diet and physical activity.

GLP-1 receptor agonists induce growth hormone secretion in healthy volunteers

Pure Medical Spa offers virtual medical weight loss Illinois programs

Clinically Proven Weight Loss: Most patients lose 1020% of their body weight within 6 months

Although data from early phase trials suggest that retatrutide is well tolerated with a similar adverse event profile to GLP-1 RAs, additional research assessing long-term safety and efficacy of retatrutide in people living with obesity and/or T2D (including cardiovascular outcomes) is awaited over the next five years

A narrative review published in Cureus searched PubMed, Embase, and Scopus through August 2025, examining the intersection of GLP-1 therapy and autoimmune thyroid disease